Consensus $132.4M. The company said, "Treace is raising its full-year 2022 revenue guidance to $135 million to $138 million, which represents approximately 43% to 46% growth over the Company’s 2021 revenue. This compares to the prior revenue guidance of $130 million to $134 million."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on TMCI:
- Treace Announces Participation in Upcoming Investor Conferences
- Treace to Report Third Quarter 2022 Financial Results on November 8, 2022
- Treace Medical Concepts Appoints New Directors
- Treace Medical price target raised to $28 from $23 at BTIG
- Treace Medical price target raised to $27 from $24 at Stifel
